Novartis withdraws imatinib MAA for PAH

Novartis AG (NYSE:NVS; SIX:NOVN) withdrew an MAA from EMA for imatinib to treat pulmonary arterial hypertension (PAH). The pharma, which submitted the application last February, said it made the decis...